The benefits and risks of alemtuzumab in multiple sclerosis

被引：0
作者：
Ontaneda, Daniel [1 ]
Cohen, Jeffrey A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期
关键词：
alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;
D O I：
10.1586/ECI.13.1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [41] The Outlook for Alemtuzumab in Multiple Sclerosis
    Williams, Thomas
    Coles, Alasdair
    Azzopardi, Laura
    BIODRUGS, 2013, 27 (03) : 181 - 189
  • [42] How Patients With Multiple Sclerosis Weigh Treatment Risks and Benefits
    Bruce, Jared M.
    Jarmolowicz, David P.
    Lynch, Sharon
    Thelen, Joanie
    Lim, Seung-Lark
    Smith, Julia
    Catley, Delwyn
    Bruce, Amanda S.
    HEALTH PSYCHOLOGY, 2018, 37 (07) : 680 - 690
  • [43] Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
    Clerico, Marinella
    De Mercanti, Stefania
    Artusi, Carlo Alberto
    Durelli, Luca
    Naismith, Robert T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 874 - 876
  • [44] Alemtuzumab-induced remission of multiple sclerosis-associated uveitis
    Willis, Mark D.
    Pickersgill, Trevor P.
    Robertson, Neil P.
    Lee, Richard W. J.
    Dick, Andrew D.
    Carreno, Ester
    INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (05) : 1229 - 1233
  • [45] Treatment of Multiple Sclerosis with the Interferon-βsComparative Risks and Benefits
    Robert McCulloch Herndon
    BioDrugs, 1998, 10 : 463 - 470
  • [46] Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
    Wang, Li
    Qi, Chun-Hui
    Zhong, Ren
    Yuan, Chao
    Zhong, Qiu-Yue
    MEDICINE, 2018, 97 (08)
  • [47] Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment
    Kantorova, Ema
    Vitkova, Marianna
    Martinikova, Martina
    Cimprichova, Andrea
    Fedicova, Miriam
    Kovacova, Slavomira
    Mako, Miroslav
    Cisar, Juraj
    Hancinova, Viera
    Szilasiova, Jarmila
    Koleda, Peter
    RohaIova, Jana
    Poloniova, Jana
    Karlik, Martin
    Slezakova, Darina
    Klimova, Eleonora
    Maciak, Matus
    Kurca, Egon
    Hnilicova, Petra
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [48] Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Gilmore, Wendy
    Lund, Brett T.
    Li, Peili
    Levy, Alex M.
    Kelland, Eve E.
    Akbari, Omid
    Groshen, Susan
    Cen, Steven Yong
    Pelletier, Daniel
    Weiner, Leslie P.
    Javed, Adil
    Dunn, Jeffrey E.
    Traboulsee, Anthony L.
    JOURNAL OF NEUROINFLAMMATION, 2020, 17 (01)
  • [49] Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up
    Hyun, Jae-Won
    Shin, Hyun-June
    Jang, Hyunmin
    Park, Na Young
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2019, 15 (03): : 328 - 333
  • [50] Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects
    Kousin-Ezewu, Onajite
    Coles, Alasdair
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2013, 4 (03) : 97 - 103
12345